Basiliximab induction improves the outcome of renal transplants in children and adolescents

A. Swiatecka-Urban, C. Garcia, D. Feuerstein, S. Suzuki, P. Devarajan, R. Schechner, Stuart M. Greenstein, V. Tellis, Frederick J. Kaskel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacrolimus and steroids (non-basiliximab group). The 1-year patient survival rate was 100% in both groups. The 1-year graft survival rate was 87.5% for the basiliximab group and 75% for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26% and 43%, respectively (P=0.36). However, in recipients with ≤3 HLA mismatches, the rate of acute rejection was zero in the basiliximab group, and 40% in the non-basiliximab group (P=0.04). The beneficial effect occurred despite the fact that tacrolimus was maintained at below the target levels. There were no adverse events directly attributable to the administration of basiliximab. There were no cases of opportunistic infections or post-transplant lymphoproliferative disease. In summary, addition of basiliximab to tacrolimus and prednisone significantly decreased the rate of acute rejection in well-matched patients. Moreover, this effect was manifest at lower, and therefore less toxic, tacrolimus levels.

Original languageEnglish (US)
Pages (from-to)693-696
Number of pages4
JournalPediatric Nephrology
Volume16
Issue number9
DOIs
StatePublished - 2001

Fingerprint

Tacrolimus
Transplants
Kidney
Survival Rate
Steroids
Poisons
Opportunistic Infections
Graft Survival
Prednisone
basiliximab

Keywords

  • Basiliximab
  • Post-transplant diabetes mellitus
  • Post-transplant lymphoproliferative disease
  • Tacrolimus
  • Target levels

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Swiatecka-Urban, A., Garcia, C., Feuerstein, D., Suzuki, S., Devarajan, P., Schechner, R., ... Kaskel, F. J. (2001). Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatric Nephrology, 16(9), 693-696. https://doi.org/10.1007/s004670100642

Basiliximab induction improves the outcome of renal transplants in children and adolescents. / Swiatecka-Urban, A.; Garcia, C.; Feuerstein, D.; Suzuki, S.; Devarajan, P.; Schechner, R.; Greenstein, Stuart M.; Tellis, V.; Kaskel, Frederick J.

In: Pediatric Nephrology, Vol. 16, No. 9, 2001, p. 693-696.

Research output: Contribution to journalArticle

Swiatecka-Urban, A, Garcia, C, Feuerstein, D, Suzuki, S, Devarajan, P, Schechner, R, Greenstein, SM, Tellis, V & Kaskel, FJ 2001, 'Basiliximab induction improves the outcome of renal transplants in children and adolescents', Pediatric Nephrology, vol. 16, no. 9, pp. 693-696. https://doi.org/10.1007/s004670100642
Swiatecka-Urban A, Garcia C, Feuerstein D, Suzuki S, Devarajan P, Schechner R et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatric Nephrology. 2001;16(9):693-696. https://doi.org/10.1007/s004670100642
Swiatecka-Urban, A. ; Garcia, C. ; Feuerstein, D. ; Suzuki, S. ; Devarajan, P. ; Schechner, R. ; Greenstein, Stuart M. ; Tellis, V. ; Kaskel, Frederick J. / Basiliximab induction improves the outcome of renal transplants in children and adolescents. In: Pediatric Nephrology. 2001 ; Vol. 16, No. 9. pp. 693-696.
@article{dd19cc329a0f4375a67e7c82f877fd96,
title = "Basiliximab induction improves the outcome of renal transplants in children and adolescents",
abstract = "Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacrolimus and steroids (non-basiliximab group). The 1-year patient survival rate was 100{\%} in both groups. The 1-year graft survival rate was 87.5{\%} for the basiliximab group and 75{\%} for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26{\%} and 43{\%}, respectively (P=0.36). However, in recipients with ≤3 HLA mismatches, the rate of acute rejection was zero in the basiliximab group, and 40{\%} in the non-basiliximab group (P=0.04). The beneficial effect occurred despite the fact that tacrolimus was maintained at below the target levels. There were no adverse events directly attributable to the administration of basiliximab. There were no cases of opportunistic infections or post-transplant lymphoproliferative disease. In summary, addition of basiliximab to tacrolimus and prednisone significantly decreased the rate of acute rejection in well-matched patients. Moreover, this effect was manifest at lower, and therefore less toxic, tacrolimus levels.",
keywords = "Basiliximab, Post-transplant diabetes mellitus, Post-transplant lymphoproliferative disease, Tacrolimus, Target levels",
author = "A. Swiatecka-Urban and C. Garcia and D. Feuerstein and S. Suzuki and P. Devarajan and R. Schechner and Greenstein, {Stuart M.} and V. Tellis and Kaskel, {Frederick J.}",
year = "2001",
doi = "10.1007/s004670100642",
language = "English (US)",
volume = "16",
pages = "693--696",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Basiliximab induction improves the outcome of renal transplants in children and adolescents

AU - Swiatecka-Urban, A.

AU - Garcia, C.

AU - Feuerstein, D.

AU - Suzuki, S.

AU - Devarajan, P.

AU - Schechner, R.

AU - Greenstein, Stuart M.

AU - Tellis, V.

AU - Kaskel, Frederick J.

PY - 2001

Y1 - 2001

N2 - Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacrolimus and steroids (non-basiliximab group). The 1-year patient survival rate was 100% in both groups. The 1-year graft survival rate was 87.5% for the basiliximab group and 75% for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26% and 43%, respectively (P=0.36). However, in recipients with ≤3 HLA mismatches, the rate of acute rejection was zero in the basiliximab group, and 40% in the non-basiliximab group (P=0.04). The beneficial effect occurred despite the fact that tacrolimus was maintained at below the target levels. There were no adverse events directly attributable to the administration of basiliximab. There were no cases of opportunistic infections or post-transplant lymphoproliferative disease. In summary, addition of basiliximab to tacrolimus and prednisone significantly decreased the rate of acute rejection in well-matched patients. Moreover, this effect was manifest at lower, and therefore less toxic, tacrolimus levels.

AB - Thirty-two children and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four patients received basiliximab, in addition to tacrolimus and steroids (basiliximab group). The remaining eight patients received only tacrolimus and steroids (non-basiliximab group). The 1-year patient survival rate was 100% in both groups. The 1-year graft survival rate was 87.5% for the basiliximab group and 75% for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26% and 43%, respectively (P=0.36). However, in recipients with ≤3 HLA mismatches, the rate of acute rejection was zero in the basiliximab group, and 40% in the non-basiliximab group (P=0.04). The beneficial effect occurred despite the fact that tacrolimus was maintained at below the target levels. There were no adverse events directly attributable to the administration of basiliximab. There were no cases of opportunistic infections or post-transplant lymphoproliferative disease. In summary, addition of basiliximab to tacrolimus and prednisone significantly decreased the rate of acute rejection in well-matched patients. Moreover, this effect was manifest at lower, and therefore less toxic, tacrolimus levels.

KW - Basiliximab

KW - Post-transplant diabetes mellitus

KW - Post-transplant lymphoproliferative disease

KW - Tacrolimus

KW - Target levels

UR - http://www.scopus.com/inward/record.url?scp=0034874885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034874885&partnerID=8YFLogxK

U2 - 10.1007/s004670100642

DO - 10.1007/s004670100642

M3 - Article

VL - 16

SP - 693

EP - 696

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 9

ER -